“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !

there could be a cure/preventative for breast cancer out there

They have a great product treating cancer with immunotherapy, peer reviewed journal

Alzheimer therapies are on the top of choices.

A drug that actually helps without any major side effects .. and breakthrough therapy. .

Better than chemo.

$AVXL The oral Anavex 2-73 therapy met the primary and secondary endpoints of the trial, with patients receiving the therapy experiencing statistically significant improvement in cognition.

$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.

$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)

These patients experienced about 35% longer survival than has been reported for other second-line therapies.

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

* Best Available Therapy offers 6-8 months of Overall Survival * All pooled Regal patients, BAT and Gps combined, is 16 months.

Good cancer stock from what I hear in 2028.

$MRK Ovarian cancer data final P2 results are better than any other drugs by a mile.

They address a broad range of cancer indications.

$SLS Gps arm 22 months of median Overall Survival Best Available Therapy 8.

$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.

The nation’s best means the O'Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.